GSK’s niraparib meets PFS goal in phase 3 PRIMA trial

This article was originally published here

Niraparib delivered the desired result when given as monotherapy in the patient population, irrespective of biomarker status. The results of the PRIMA trial were presented at the 2019

The post GSK’s niraparib meets PFS goal in phase 3 PRIMA trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply